

GSK contract, UK clearance for CT:VQ™, and ASX 200 inclusion

20 April 2026

Highlights

- Contract executed with GlaxoSmithKline (GSK), one of the world's largest pharmaceutical companies, to supply 4DMedical's functional lung imaging analytics in support of pulmonary drug development
- CT:VQ™ receives UKCA certification for clinical use in the United Kingdom, expanding 4DMedical's European footprint following CE Mark certification in March 2026
- UK clearance opens access to one of the world's most developed diagnostic imaging markets, with millions of chest CT scans performed annually across respiratory, oncology and acute care pathways
- Coronary Artery Calcium (CAC) analysis cleared in Canada, coinciding with 4DMedical's participation at the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Montreal
- CMS establishes a new US reimbursement pathway for AI-based opportunistic coronary calcium analysis from routine chest CT scans, enabling scalable clinical and commercial adoption
- 4DMedical included in the S&P/ASX 200 Index, effective prior to the open of trading today

Melbourne, Australia, 20 April 2026 – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, today announces a series of commercial, regulatory and corporate milestones that further expand global market access and validate demand for its advanced cardiopulmonary imaging analytics platform.

Strategic pharmaceutical engagement with GSK

4DMedical has entered a contractual engagement with GlaxoSmithKline (GSK), in association with leading imaging data platform Flywheel Exchange, to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research.

Under the one-year agreement, 4DMedical will supply advanced lung imaging biomarkers from its software analytics platform, enabling sensitive, quantitative assessment of lung structure and function across clinical trial cohorts. The contract commences on 1 May 2026. The contract value is commercially confidential and is not individually material.

The engagement with one of the world's largest pharmaceutical companies reflects increasing adoption of 4DMedical's analytics platform by global biopharmaceutical companies seeking scalable, reproducible imaging endpoints to improve trial efficiency, patient stratification, and longitudinal disease assessment. The GSK contract builds on 4DMedical's established pharmaceutical relationships, including its ongoing engagement with AstraZeneca, and reinforces the Company's position as a preferred provider of quantitative imaging analytics for respiratory drug development.

UK clearance for CT:VQ™ expands European footprint

CT:VQ™ continues to be 4DMedical's primary commercial growth driver in the United States, where FDA clearance has enabled deployment across leading Academic Medical Centers (AMCs) and positioned the technology at the forefront of next-generation functional lung imaging. CT:VQ™ is now deployed at six leading U.S. AMCs, with additional institutions actively evaluating the technology.



The Company is pleased to advise that, following the receipt of CE Mark certification in March 2026, CT:VQ™ has now obtained UKCA certification for clinical use in the United Kingdom, under the regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA). This regulatory clearance allows for the immediate commercial deployment of CT:VQ™ across both public and private healthcare providers within the UK.

The UK represents one of the world's most developed diagnostic imaging environments. Millions of chest CT scans are performed annually, with CT forming a core diagnostic tool for lung cancer screening, COPD, interstitial lung disease, pulmonary embolism, and acute care workflows. CT:VQ™ is uniquely positioned to integrate into these established pathways by delivering quantitative ventilation and perfusion insights from routine non-contrast CT scans, without the complexity or constraints of nuclear medicine.

Europe and the UK play a critical role in shaping global respiratory medicine and imaging practice. Institutions such as the Royal Brompton Hospital in London, where 4DMedical clinical research is underway, are internationally recognised centres of excellence in cardiopulmonary research and clinical care, with strong collaborative ties to North American AMCs. UK clearance enables 4DMedical to engage directly with leading European and UK clinicians, support investigator-initiated research, and contribute to the global clinical evidence base underpinning CT:VQ™. This engagement is complementary to the Company's US commercial strategy and reinforces the long-term clinical credibility of its platform.

With UKCA and CE Mark certifications now in hand, 4DMedical holds regulatory clearance for CT:VQ™ across the United States, the European Union, the United Kingdom, Canada, and New Zealand.

CAC clearance in Canada

The Company confirms that its Coronary Artery Calcium (CAC) analysis solution has received regulatory clearance from Health Canada, permitting clinical use across Canadian healthcare institutions. This milestone coincides with 4DMedical's attendance at the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Montreal over the weekend, where the Company presented its expanding cardiopulmonary imaging portfolio to radiologists, researchers and health system leaders.

▶ REGULATORY COMPLIANCE – REGULATORY STATUS



	FDA (USA)	CE Mark (EU)	TGA (AU)	CMDR (Canada)	MHRA (UK)	Medsafe (NZ)	ANVISA (Brazil)
CAC	✓	✓	Under review	✓			
CT LVAS	✓	✓	✓	✓		✓	
CT:VQ	✓	✓	Under review	✓	✓	✓	
IQ-UIP	✓			Under review			
LDA	✓	✓	✓	✓	✓		✓
LTA		✓	✓	✓	✓		✓
PHA	✓		*				
RV/LV	✓	✓	✓				✓
XV LVAS	✓		✓			✓	



CAC reimbursement milestone in US

In the United States, the Centers for Medicare & Medicaid Services (CMS) has established HCPCS code G0680, creating a dedicated reimbursement pathway for AI-enabled opportunistic analysis of coronary artery calcium from routine chest CT scans. The code provides reimbursement of US\$15.50 per study in the hospital outpatient setting.

The creation of a specific reimbursement code for AI-enabled opportunistic CAC analysis represents an important market-creation event, establishing the economic infrastructure for broader clinical adoption without requiring dedicated cardiac CT imaging or additional scan time.

4DMedical included in S&P/ASX 200 Index

4DMedical will be included in the S&P/ASX 200 Index, effective prior to the open of trading today. The ASX 200 is Australia's primary benchmark equity index, representing the largest 200 companies by market capitalisation. Inclusion broadens 4DMedical's institutional shareholder base and increases visibility among index-tracking and passive investment funds.

The Company's inclusion in the ASX 200 reflects the significant progress achieved over the past twelve months, including: FDA clearance of CT:VQ™ in September 2025; deployment of CT:VQ™ at six leading U.S. AMCs including Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, Mayo, and University of Miami; execution of the Philips distribution agreement for CT:VQ™; CE Mark certification enabling access to the European Union; and the growing pharmaceutical engagement with companies including AstraZeneca and now GSK. Together, these milestones have driven a material re-rating of the Company and its progression into the ASX 200.

4DMedical MD/CEO and Founder Andreas Fouras said:

Our engagement with GSK demonstrates the growing importance of 4DMedical's quantitative imaging analytics in pharmaceutical development. As biopharmaceutical companies seek more sensitive, reproducible endpoints to support respiratory drug development, our platform is increasingly well positioned to serve this expanding market alongside our established clinical business. Importantly, this engagement also creates the potential to support programs beyond development, including the future use of our technology as a companion diagnostic as therapies progress through to commercialisation.

UK clearance for CT:VQ™ gives us access to one of the most sophisticated imaging markets in the world. Combined with CE Mark certification, 4DMedical now holds regulatory clearance for CT:VQ™ across every major Western healthcare market. The UK is home to some of the world's most influential cardiopulmonary centres, and our ability to engage directly with these institutions strengthens the global evidence base and clinical credibility of our platform.

Collectively, milestones such as pharmaceutical engagement with a global leader, expanding geographic reach, a growing cardiopulmonary portfolio, and inclusion in the ASX 200, reinforce 4DMedical's position as a global platform company in CT-based cardiopulmonary imaging. However, what excites me most is what lies ahead. Our commercial pipeline is the deepest and most advanced it has ever been, and I look forward to updating shareholders shortly.

—ENDS—

Authorised by the 4DMedical Board of Directors.



Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com